Information on reimbursement for the cost of medications provided at Provis Infusion Clinic Inc.
- The cost of IV chemotherapeutic agents infused at the Provis Infusion Clinic, plus a fee for the clinic’s service, is charged to the patient .
- In some cases, the patient’s 3rd party insurers may cover all or part of the drug cost and will reimburse the patient directly
- Additionally, there may be an assistance program for the medication you require that may be able to help with additional reimbursement. Please contact us for more information.
Please note: payment for treatment is due to Provis Infusion Clinic prior to the commencement of treatment.
Does your Plan cover the medication you need?
If you are not sure if a medication is covered by your private insurance plan, your insurance carrier must be contacted to determine the extent of your coverage. We will need to supply the insurance company with your policy number or group health benefits number (if you do not know this number, the Human Resources manager at your employer will have it). The insurance carrier will also require the name of the drug and the drug information number (DIN) of the particular medication you are prescribed. Please contact our Clinic Administrator for further information or if you have any questions. The following are the medications currently provided at Provis Infusion Clinic:
Medication - DIN
Abraxane™ - 02281066
Alimta™ - 02253437
Avastin® - 02270994
Caelyx® - 02238389
Carboplatin - 02125439
Cisplatin - 02126613
Eloxatin® - 02296268
Erbitux® - 02271249
Gemzar™ - 02230309
Halaven® - 02377438
Herceptin® - 02240692
Jevtana® - 02369524
Perjeta® – 02405016
Remicade® - 02244016
Rituxan® - 02241927
Taxotere® - 02177099/02177080
Topotecan® - 02344009
Torisel® - 02304104
Treanda® - 02392569
Vectibix® - 02308487
Venofer® - 02243716
Velcade® - 02262452
Zometa® - 02242725
For information on Private Insurance Plans (types of plans, coverage of medications, copays, deductibles, special authorization for reimbursement of certain medications, appealing refused claims, etc.) See this link: http://drugcoverage.ca/en-ca/
Why Choose Provis?
- Infusion Services Since 2005
- Over 13,000+ Infusions To Date
- Most Comprehensive Oncology Drug Formulary in Canada
- Onsite Medication Compounding Facility
- Experienced Pharmacists On-Site
- Experienced Oncology Trained Nurses
- Supervising Physician On-Site
14 Year Anniversary!The Provis Infusion Clinic is please to announce that August 2017 marks the 14 anniversary of the Provis Infusion Clinic. We are looking forward to the next 14 years of providing high quality infusion services.
Expanded Indications for OPDIVO™ and KEYTRUDA™OPDIVO™ is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving OPDIVO™. KEYTRUDA™ has received NOC with Conditions for use in the treatment of patients with: Metastatic NSCLC whose tumours express PD-L1 and who have a disease progression on or after platinum-containing chemotherapy. patients with EGFR or ALK genomic tumour aberrations should have disease progression on authorized therapy for these aberrations prior to receiving KEYTRUDA™.
New MedicationsVenofer™ (Iron Sucrose) Onivyde™ (Irinotecan liposome for injection) Tecentriq™ (Atezolizumab) Renflexis™ (Infliximab) Yondelis™ (Trabectedin)
Kyprolis™ (Carfilzomib) receives Health Canada approval.Health Canada has approved Kyprolis™ (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
Opdivo™ (Nivolumab) receives Health Canada approval.Opdivo™ is the first anti PD-1 (programmed death-1) approved to treat previously untreated cases of BRAF V600 wild-type unresectable or metastatic melanoma in adults. The approval was made under the Health Canada Priority Review process, after having met the criteria of substantial evidence of clinical effectiveness providing an improved benefit/risk profile over existing therapies. Provis is also able to provide Opdivo™ for other indications if required.
Keytruda™ (Pembrolizumab) now offered at ProvisAUTHORIZATION WITH CONDITIONS OF KEYTRUDA™ for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor
Update – Patient Support Programs
Keytruda®, Perjeta®, Herceptin®, Avastin®,Jevtana®, Rituxan®, Abraxane®, Treanda® Kadcyla® and Kyprolis® Patients: Provis participates in the Roche Patient Assistance Program, the Treanda Support Program, the Merck Care Oncology, Kyprolis (Victory) and Celgene Abraxane® Access Program . These program offers financial assistance to qualified patients receiving Kyprolis®, Keytruda®, Perjeta®, Herceptin®, Avastin®, Rituxan®, Abraxane®,Treanda® and Kadcyla® Read More >>
Non-Muscle Invasive Bladder CancerProvis works with the University Urology Associates (UUA), in providing the compounded MMC for electronically stimulated Mitomycin-C (EMDA MMC) to treat non-muscle invasive bladder cancer.
The Ride to Conquer CancerThe Provis Pelotons Cycling Team participate in the 2015 Ride to Conquer Cancer. The ride is over 220km's from Toronto to Niagara Falls. The team raised close to $13,000 for cancer research. Way to go Graham, Deb, Steve, Samantha and Dave.